Analyst consensus rating
Candel Therapeutics Analyst Rating: none
Direct answer
Candel Therapeutics's consensus rating is none.
8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $21.00.
Forecast evidence checked September 8, 2026.
Get free Candel Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $12.76
- Average price target
- $21.00
- High price target
- $29.00
- Low price target
- $12.00
- Low target gap
- -6%
- Target upside
- +64.5%
- High target gap
- +127.2%
- Target range width
- 133.2%
- Consensus rating
- none
- Analysts
- 8
- Evidence date
- September 8, 2026
- Valid through
- September 15, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Candel Therapeutics?
Candel Therapeutics has a verified none consensus. The same dataset has an average price target of $21.00.
How far are Candel Therapeutics's low and high targets from the recorded price?
The low target implies -6%, while the high target implies +127.2%.
How many analysts are included in Candel Therapeutics's consensus?
The verified consensus includes 8 analysts.
How is Candel Therapeutics's target upside or downside calculated?
The average target of $21.00 is divided by the recorded price of $12.76, then one is subtracted to produce +64.5%. This does not guarantee a future return.
When was Candel Therapeutics's analyst forecast verified?
The data was verified on 2026-09-08. The dataset is valid through 2026-09-15.